BP-C1 in the treatment of patients with stage IV breast cancer: a randomized, double-blind, placebo-controlled multicenter study and an additional open-label treatment phase

por Larsen, Stig, Butthongkomvong, Kritiya, Manikhas, Alexey, Trishkina, Ekaterina, Poddubuskaya, Elena, Matrosova, Marina, Srimuninnimit, Vichien, Lindkær-Jensen, Steen
Publicado 2014

Safety and efficacy of adjuvant subcutaneous trastuzumab in human epidermal growth factor receptor 2-positive early breast cancer: Final results of the SafeHER study

por Gligorov, Joseph, Pivot, Xavier, Ataseven, Beyhan, De Laurentiis, Michelino, Jung, Kyung Hae, Manikhas, Alexey, Abdel Azim, Hamdy, Gupta, Kushagra, Alexandrou, Ari, Herraez-Baranda, Luis, Tosti, Nadia, Restuccia, Eleonora
Publicado 2022

Long-term efficacy and safety of CT-P6 versus trastuzumab in patients with HER2-positive early breast cancer: final results from a randomized phase III trial

por Stebbing, Justin, Baranau, Yauheni V., Baryash, Valery, Manikhas, Alexey, Moiseyenko, Vladimir, Dzagnidze, Giorgi, Zhavrid, Edvard, Boliukh, Dmytro, Pikiel, Joanna, Eniu, Alexandru E., Li, Rubi K., Tiangco, Beatrice, Lee, Sang Joon, Kim, Sunghyun
Publicado 2021

A randomized phase II study of lapatinib + pazopanib versus lapatinib in patients with HER2+ inflammatory breast cancer

por Cristofanilli, Massimo, Johnston, Stephen R. D., Manikhas, Alexey, Gomez, Henry L., Gladkov, Oleg, Shao, Zhimin, Safina, Sufia, Blackwell, Kimberly L., Alvarez, Ricardo H., Rubin, Stephen D., Ranganathan, Sulabha, Redhu, Suman, Trudeau, Maureen E.
Publicado 2012

Six-Year Survival Outcomes for Patients with HER2-Positive Early Breast Cancer Treated with CT-P6 or Reference Trastuzumab: Observational Follow-Up Study of a Phase 3 Randomised Co...

por Stebbing, Justin, Baranau, Yauheni, Baryash, Valery, Moiseyenko, Vladimir, Boliukh, Dmytro, Antone, Nicoleta, Manikhas, Alexey, Chornobai, Anatolii, Park, Taehong, Baek, Eric Hyungseok, Lee, Jaeyong, Choi, Jiin, Kim, Nahyun, Ahn, Keumyoung, Lee, Sang Joon, Kim, Sunghyun
Publicado 2023

Final analysis of the phase 3 randomized clinical trial comparing HD201 vs. referent trastuzumab in patients with ERBB2-positive breast cancer treated in the neoadjuvant setting

por Pivot, Xavier, Manikhas, Alexey Georgievitch, Shamrai, Volodymyr, Dzagnidze, Giorgi, Soo Hoo, Hwoei Fen, Kaewkangsadan, Viriya, Petrelli, Fausto, Villanueva, Cristian, Kim, Jamie, Pradhan, Sumita, Jaison, Litha, Feyaerts, Peggy, Kaufman, Leonard, Derde, Marie-Paule, Deforce, Filip, Cox, David G.
Publicado 2023

Correlation between week 24 trastuzumab-dkst response and week 48 progression-free survival: the HERITAGE trial

por Rugo, Hope S., Pennella, Eduardo J., Gopalakrishnan, Unmesh, Hernandez-Bronchud, Miguel, Herson, Jay, Koch, Hans Friedrich, Loganathan, Subramanian, Deodhar, Sarika, Marwah, Ashwani, Manikhas, Alexey, Bondarenko, Igor, Parra, Joseph D., Abesamis-Tiambeng, Maria Luisa T., Akewanlop, Charuwan, Vynnychenko, Ihor, Sriuranpong, Virote, Roy, Sirshendu, Yanez Ruiz, Eduardo Patricio, Barve, Abhijit, Waller, Cornelius F.
Publicado 2021

Final overall survival analysis of the phase 3 HERITAGE study demonstrates equivalence of trastuzumab-dkst to trastuzumab in HER2-positive metastatic breast cancer

por Rugo, Hope S., Pennella, Eduardo J., Gopalakrishnan, Unmesh, Hernandez-Bronchud, Miguel, Herson, Jay, Koch, Hans Friedrich, Loganathan, Subramanian, Deodhar, Sarika, Marwah, Ashwani, Manikhas, Alexey, Bondarenko, Igor, Mukhametshina, Guzel, Nemsadze, Gia, Parra, Joseph D., Abesamis-Tiambeng, Maria Luisa T., Baramidze, Kakhaber, Akewanlop, Charuwan, Vynnychenko, Ihor, Sriuranpong, Virote, Mamillapalli, Gopichand, Roy, Sirshendu, Yanez Ruiz, Eduardo Patricio, Barve, Abhijit, Fuentes-Alburo, Adolfo, Waller, Cornelius F.
Publicado 2021